Sponsor ID: AZ-2024-0892 · Last Updated: 2024-11-15 · Location: Neo Geneva, Global HQ
Aevum Zenth Conglomerate is a multidivisional enterprise with a leading biomedical research division focused on oncology, neurodegenerative diseases, regenerative medicine, gene therapies, and AI-driven drug discovery platforms.
| NCT Identifier | Trial Title | Phase | Status | Conditions | Start Date |
|---|---|---|---|---|---|
| NCT06388291 | Biomarker Validation for AZN-5509 in Solid Tumor Metastasis | Phase 1 | Not Yet Recruiting | Neoplasm Metastasis; Carcinoma; Tumor Biomarkers | 2024-06-01 |
| NCT06310442 | CAR-T Cell Therapy (ZENTH-CD19) for Relapsed/Refractory B-Cell ALL | Phase 2 | Recruiting | Acute Lymphoblastic Leukemia; Hematologic Neoplasms | 2024-03-11 |
| NCT06294105 | Gene Therapy Using AAV9 Vector for Duchenne Muscular Dystrophy | Phase 2 | Recruiting | Duchenne Muscular Dystrophy; Muscle Weakness; Dystrophinopathy | 2024-01-22 |
| NCT06245108 | Real-World Evidence Study of AZN-9921 in Chronic Hepatitis C | Phase 4 | Completed | Hepatitis C, Chronic; Liver Cirrhosis; Viral Hepatitis | 2023-12-10 |
| NCT06211593 | Phase 3 Randomized Trial of AZN-1174 vs Standard of Care in Type 2 Diabetes | Phase 3 | Recruiting | Diabetes Mellitus Type 2; Metabolic Syndrome; Glucose Intolerance | 2023-09-19 |
| NCT06182934 | Efficacy and Safety of AZN-4421 in Advanced Non-Small Cell Lung Cancer | Phase 3 | Recruiting | Lung Neoplasms; NSCLC; Oncogene-Addicted Cancers | 2023-08-14 |
| NCT06102744 | Phase 2 Trial of Dual PI3K/mTOR Inhibitor in Pediatric Brain Tumors | Phase 2 | Recruiting | Glioma; Medulloblastoma; Pediatric Neoplasms | 2023-05-14 |
| NCT06045881 | Longitudinal Safety Study of Bioengineered Cardiac Patches | Phase 1 | Enrolling by Invitation | Myocardial Infarction; Heart Failure; Regenerative Medicine | 2023-02-28 |
| NCT05988217 | AI-Guided Dose Optimization for AZP-889 in Alzheimer's Disease | Phase 1 | Completed | Alzheimer Disease; Mild Cognitive Impairment; Neurodegeneration | 2022-11-05 |
| NCT05877420 | Neuroregenerative Effects of Stem Cell-Derived Oligodendrocytes in MS | Phase 2 | Completed | Multiple Sclerosis; Neuromyelitis Optica; Demyelinating Diseases | 2022-06-07 |